Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mustang Bio Inc MBIO

Healthcare Biotechnology
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs in cell and gene therapies into potential cures for cancers and rare genetic diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR-T) therapies across multiple cancers, as well as lentiviral gene... see more

Recent & Breaking News (NDAQ:MBIO)

Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

GlobeNewswire March 28, 2024

Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

GlobeNewswire March 11, 2024

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

GlobeNewswire March 7, 2024

Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

GlobeNewswire January 11, 2024

Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting

GlobeNewswire December 11, 2023

Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

GlobeNewswire November 14, 2023

Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting

GlobeNewswire November 2, 2023

Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire October 30, 2023

Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire October 26, 2023

Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma

GlobeNewswire October 26, 2023

Mustang Bio to Participate in Upcoming September 2023 Investor Conferences

GlobeNewswire September 7, 2023

Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

GlobeNewswire August 16, 2023

Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

GlobeNewswire August 14, 2023

Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

GlobeNewswire August 14, 2023

Mustang Bio to Participate in Two August 2023 Investor Conferences

GlobeNewswire August 3, 2023

Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences

GlobeNewswire July 31, 2023

Mustang Bio Announces Participation in Upcoming Scientific Meetings

GlobeNewswire July 6, 2023

Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

GlobeNewswire June 15, 2023

Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

GlobeNewswire June 12, 2023

Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates

GlobeNewswire May 18, 2023